Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
47 ud af 47 tidsskrifter valgt, søgeord (corona) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
304 emner vises.
Shin Jie Yong; Alice Halim; Michael Halim; Shiliang Liu; Mohammed Aljeldah; Basim R. Al Shammari; Sara Alwarthan; Mashael Alhajri; Abdulsalam Alawfi; Amer Alshengeti; Faryal Khamis; Jameela Alsalman; Abeer N. Alshukairi; Nujoud A. Abukhamis; Fatimah S. Almaghrabi; Souad A. Almuthree; Abdulrahman M. Alsulaiman; Bashayer M. Alshehail; Amal H. Alfaraj; Shorouq A. Alhawaj; Ranjan K. Mohapatra; Ali A. Rabaan;
Reviews in Medical Virology, 24.04.2023
Tilføjet 24.04.2023
Severe acute respiratory syndrome coronavirus 2 may inflict a post‐viral condition known as post‐COVID‐19 syndrome (PCS) or long‐COVID. Studies measuring levels of inflammatory and vascular biomarkers in blood, serum, or plasma of COVID‐19 survivors with PCS versus non‐PCS controls have produced mixed findings. Our review sought to meta‐analyse those studies. A systematic literature search was performed across five databases until 25 June 2022, with an updated search on 1 November 2022. Data analyses were performed with Review Manager and R Studio statistical software. Twenty‐four biomarkers from 23 studies were meta‐analysed. Higher levels of C‐reactive protein (Standardized mean difference (SMD) = 0.20; 95% CI: 0.02–0.39), D‐dimer (SMD = 0.27; 95% CI: 0.09–0.46), lactate dehydrogenase (SMD = 0.30; 95% CI: 0.05–0.54), and leukocytes (SMD = 0.34; 95% CI: 0.02–0.66) were found in COVID‐19 survivors with PCS than in those without PCS. After sensitivity analyses, lymphocytes (SMD = 0.30; 95% CI: 0.12–0.48) and interleukin‐6 (SMD = 0.30; 95% CI: 0.12–0.49) were also significantly higher in PCS than non‐PCS cases. No significant differences were noted in the remaining biomarkers investigated (e.g., ferritin, platelets, troponin, and fibrinogen). Subgroup analyses suggested the biomarker changes were mainly driven by PCS cases diagnosed via manifestation of organ abnormalities rather than symptomatic persistence, as well as PCS cases with duration of
Læs mere Tjek på PubMedArto Yuwono Soeroto; Theo Audi Yanto; Andree Kurniawan; Timotius Ivan Hariyanto;
Reviews in Medical Virology, 24.04.2023
Tilføjet 24.04.2023
Some proportions of populations, such as immunocompromised patients and organ transplant recipients might have inadequate immune responses to the vaccine for coronavirus disease 2019 (COVID‐19). For these groups of populations, administering monoclonal antibodies might offer some additional protection. This review sought to analyze the effectiveness and safety of tixagevimab‐cilgavimab (Evusheld) as pre‐exposure prophylaxis against COVID‐19. We used specific keywords to comprehensively search for potential studies on PubMed, Scopus, Europe PMC, and sources until 3 September 2022. We collected all published articles that analyzed tixagevimab‐cilgavimab on the course of COVID‐19. Review Manager 5.4 was utilized for statistical analysis. Six studies were included. Our pooled analysis revealed that tixagevimab‐cilgavimab prophylaxis may decrease the rate of SARS‐CoV‐2 infection (OR: 0.24; 95% CI: 0.15–0.40,
Læs mere Tjek på PubMedWenli Shang; Yingying Zhang; Guizuo Wang; Dong Han;
Reviews in Medical Virology, 24.04.2023
Tilføjet 24.04.2023
The Coronavirus disease‐2019 (COVID‐19) pandemic continues, and the death toll continues to surge. This meta‐analysis aimed to determine the efficacy of anakinra on mortality in patients with COVID‐19. A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials on treatment of COVID‐19 with anakinra, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs). Five Randomized controlled trials (enrolling 1859 participants) met the inclusion criteria. There was no statistically significant difference in 14‐day mortality (RR 0.78, 95% CI 0.43–1.39; = 0.40), 28‐day mortality (RR 1.06, 95% CI 0.89–1.26; = 0.51), and 90‐day mortality (RR 1.01, 95% CI 0.73–1.39; = 0.97) between the two groups. Sensitivity analyses further confirmed these results. Anakinra was not associated with reduced mortality in hospitalised patients with COVID‐19. Anakinra probably should not be used routinely in COVID‐19 patients.
Læs mere Tjek på PubMedSourabh Soni; Yohannes A. Mebratu;
Reviews in Medical Virology, 24.04.2023
Tilføjet 24.04.2023
The COVID‐19 pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has led to a global health emergency. There are many similarities between SARS‐CoV‐2 and influenza A virus (IAV); both are single‐stranded RNA viruses infecting airway epithelial cells and have similar modes of replication and transmission. Like IAVs, SARS‐CoV‐2 infections poses serious challenges due to the lack of effective therapeutic interventions, frequent appearances of new strains of the virus, and development of drug resistance. New approaches to control these infectious agents may stem from cellular factors or pathways that directly or indirectly interact with viral proteins to enhance or inhibit virus replication. One of the emerging concepts is that host cellular factors and pathways are required for maintaining viral genome integrity, which is essential for viral replication. Although IAVs have been studied for several years and many cellular proteins involved in their replication and pathogenesis have been identified, very little is known about how SARS‐CoV‐2 hijacks host cellular proteins to promote their replication. IAV induces apoptotic cell death, mediated by the B‐cell lymphoma‐2 (Bcl‐2) family proteins in infected epithelia, and the pro‐apoptotic members of this family promotes viral replication by activating host cell proteases. This review compares the life cycle and mode of replication of IAV and SARS‐CoV‐2 and examines the potential roles of host cellular proteins, belonging to the Bcl‐2 family, in SARS‐CoV‐2 replication to provide future research directions.
Læs mere Tjek på PubMed